Biblioteca Humberto Rosselli Quijano
[artículo]
| Título : |
Efficacy of quetiapine in parkinson's patients with psychosis |
| Tipo de documento: |
texto impreso |
| Autores: |
Steven David Targum, Autor ; Jacob L. Abbott, Autor |
| Fecha de publicación: |
2023 |
| Artículo en la página: |
pp. 54-60 |
| Idioma : |
Inglés (eng) Idioma original : Inglés (eng) |
| Palabras clave: |
Antipsicóticos, Dibenzotiacepinas, Enfermedad de Parkinson, Psicosis inducidas por sustancias. |
| Resumen: |
Eleven patients with Parkinson's disease (PD) and acute psychosis received flexible doses of quetiapine between 25 and 300 mg/day based on clinical response and tolerance. Ten patients were receiving dopaminergic agents at baseline. Serial efficacy ratings (Brief Psychiatric Rating Scale, Clinical Global Impressions Scale), neuromuscular symptom assessments (Abnormal Involuntary Movement Scale, Simpson-Angus Scale, Unified Parkinson's Disease Rating Scale [UPDRS]), and adverse events monitoring were performed for up to 52 weeks. |
| Link: |
./index.php?lvl=notice_display&id=31232 |
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 1 (Febrero) . - pp. 54-60
[artículo] Efficacy of quetiapine in parkinson's patients with psychosis [texto impreso] / Steven David Targum, Autor ; Jacob L. Abbott, Autor . - 2023 . - pp. 54-60. Idioma : Inglés ( eng) Idioma original : Inglés ( eng) in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 1 (Febrero) . - pp. 54-60
| Palabras clave: |
Antipsicóticos, Dibenzotiacepinas, Enfermedad de Parkinson, Psicosis inducidas por sustancias. |
| Resumen: |
Eleven patients with Parkinson's disease (PD) and acute psychosis received flexible doses of quetiapine between 25 and 300 mg/day based on clinical response and tolerance. Ten patients were receiving dopaminergic agents at baseline. Serial efficacy ratings (Brief Psychiatric Rating Scale, Clinical Global Impressions Scale), neuromuscular symptom assessments (Abnormal Involuntary Movement Scale, Simpson-Angus Scale, Unified Parkinson's Disease Rating Scale [UPDRS]), and adverse events monitoring were performed for up to 52 weeks. |
| Link: |
./index.php?lvl=notice_display&id=31232 |
|
